CAMBRIDGE, Mass., May 19, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that clinical data for IPI-926, its novel Smoothened antagonist, and retaspimycin hydrochloride (IPI-504), its novel Hsp90 inhibitor, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Both investigational agents target underlying mechanisms that are responsible for malignant cell growth and survival in a broad range of difficult-to-treat cancers for which limited treatment options are available for patients. The ASCO meeting is being held from June 3 through June 7 in Chicago, Ill.
